A straightforward explanation why more COVID-19 vaccines can’t be produced with help from ‘dozens’ of companies MarketWatch 2/4/2021
OUTSIDE THE BOX
In the last few days, the question of why more drug companies haven’t been enlisted for vaccine production has come up. It’s mostly due to this tweet:
The vaccine shortage doesn t need to exist. Pfizer and Moderna could share their design with the dozens of other pharma companies who stand ready to produce their vaccines and end the pandemic. James Hamblin (@jameshamblin) February 2, 2021
The problem is, as far as I can see, this is simply wrong. There are not “dozens of other pharma companies” who “stand ready” to produce these mRNA vaccines. To me, this betrays a lack of knowledge about what these vaccines are and how they’re produced.
A straightforward explanation why more COVID-19 vaccines can’t be produced with help from ‘dozens’ of companies MarketWatch 2/4/2021
OUTSIDE THE BOX
In the last few days, the question of why more drug companies haven’t been enlisted for vaccine production has come up. It’s mostly due to this tweet:
The vaccine shortage doesn t need to exist. Pfizer and Moderna could share their design with the dozens of other pharma companies who stand ready to produce their vaccines and end the pandemic. James Hamblin (@jameshamblin) February 2, 2021
The problem is, as far as I can see, this is simply wrong. There are not “dozens of other pharma companies” who “stand ready” to produce these mRNA vaccines. To me, this betrays a lack of knowledge about what these vaccines are and how they’re produced.
2 February, 2021
In the last few days, the question of why more drug companies haven’t been enlisted for vaccine production has come up. It’s mostly due to this tweet:
The problem is, as far as I can see, this is simply wrong. There are not “dozens of other pharma companies” who “stand ready” to produce these mRNA vaccines. To me, this betrays a lack of knowledge about what these vaccines are and how they’re produced. Even though I’m not a pharma manufacturing person, I am indeed a pharma researcher in general. So I would be glad to fill in this gap, and here’s why it’s not possible to suddenly unleash dozens of companies to crank out the Pfizer/BioNTech and Moderna vaccines.
A straightforward explanation why more COVID-19 vaccines can’t be produced with help from ‘dozens’ of companies MarketWatch 2/4/2021
OUTSIDE THE BOX
In the last few days, the question of why more drug companies haven’t been enlisted for vaccine production has come up. It’s mostly due to this tweet:
The vaccine shortage doesn t need to exist. Pfizer and Moderna could share their design with the dozens of other pharma companies who stand ready to produce their vaccines and end the pandemic. James Hamblin (@jameshamblin) February 2, 2021
The problem is, as far as I can see, this is simply wrong. There are not “dozens of other pharma companies” who “stand ready” to produce these mRNA vaccines. To me, this betrays a lack of knowledge about what these vaccines are and how they’re produced.
Next generation child health in a pandemic era The London School of Hygiene & Tropical Medicine (LSHTM), together with Takeda Pharmaceutical Company, invite you to this exclusive webinar.
In 2019, Takeda partnered with LSHTM to support the first Takeda Chair in Global Child Health at LSHTM, to enable more children to survive and thrive. With Takeda’s support, LSHTM is proud to have recruited Professor Debra Jackson, a leading academic in child health, to join LSHTM and our Maternal, Adolescent, Reproductive and Child Health (MARCH) Centre.
We are delighted to invite you to our exclusive webinar. Professor Peter Piot, Director of LSHTM, and Dr Rajeev Venkayya President of the Global Vaccine Business Unit at Takeda, will introduce Professor Debra Jackson to speak about her work. Professor Debra Jackson will be joined by Professor Joy Lawn, Director of the MARCH Centre, and together they will explore a number of topics including: